Agenda. Adjuvant Bisphosphonates: Ready For Prime Time? The Osteoporosis Equation. Risk Factors for Osteoporosis. Charles L.
|
|
- Gwen Morgan
- 5 years ago
- Views:
Transcription
1 Adjuvant Bisphosphonates: eady For Prime Time? The Osteoporosis Equation Aging, family history, race, menopause [estrogen deficiency] diet, exercise, smoking, alcohol, meds Charles L. Shapiro, MD Director of Breast Medical Oncology Peak bone mass Genetics Exposures Bone Loss Ohio State University Medical Center and Comprehensive Cancer Center March 29 amaswamy and Shapiro Semin Oncol 3:763, 23 Agenda Prevention of bone loss Chemotherapy-induced and GnHinduced ovarian failure isk Factors for Osteoporosis isk factor With BMD 95% CI Body Mass Index* Prior fracture after age 5* Parental history of fracture Aromatase-inhibitor-induced bone loss Prevention of metastasis Current smoking Ever use of steroids* Alcohol intake > 2/day heumatoid Arthritis *isk factor also in men Kanis et al Osteoporosis Int 16:581-9, 25 1
2 Fractures Increase Morbidity and Mortality Prior vertebral fracture associated with: Five-fold increase in future vertebral fracture Increase in hip fracture nearly double Hip fracture: Disability: 5% (many permanently) Long-term nursing home care 25% One year mortality up to 24% Lifetime risk of death=breast cancer Multiple vertebral fractures: Increased mortality rate, particularly from pulmonary disease Non-traumatic fractures are preventable 1. oss PD et al. Ann Intern Med. 1991;114: Cummings S et al. N Engl J Med. 1995;332: iggs BL et al. Bone. 1995;17:55S-511S. 4. ay NF. J Bone Miner es. 1997;12: Cummings S et al. Arch Intern Med. 1989;149: Kado DM et al. Arch Internal Med. 1999;159: Fracture isk Increases with Lower T-scores 5-Year Fracture isk (%) Vertebral Fractures Age (years) Adapted with permission from Cummings S et al. JAMA. 22;288: Hip Fractures T-score Measuring BMD Central DEXA Gold standard Measures spine, hip, or total body BMD T-score The number of SDs by which bone mass falls above or below the mean peak bone mass for a healthy 3- year-old females For every 1 SD decrease in T-score, relative risk of fracture increases ~1.5- to 2.5-fold Causes of Bone Loss Chemo-induced ovarian failure Glucocorticoids Bilateral oophorectomy Hypogonadism Elevated bone turnover Bilateral orchiectomy Aromatase inhibitors GnH agonists T-score Normal > -1 Osteopenia -1 to -2.5 Osteoporosis < -2.5 Bone loss Fracture Pfeilschifter J et al. J Clin Oncol. 2;18:
3 Sources of Estrogen in Post vs Pre Androgens Aromatase (CYP19) Chemotherapy-Induced Ovarian Failure causes Bone Loss at 1 Year 24 month data Shapiro Fuleilhan Saarto Hershman premenopausal Estrogens % BMD -2-4 postmenopausal -6 Lumbar spine Hip Aromatase -8-1 Women with ovarian failure Adipose tissue; ovary; brain 1.Shapiro CL et al. J Clin Oncol. 21;19: Fuleihan G J Clin Endocrinol Metab 9:329-14;25 3. Saarto T et al. J Clin Oncol. 1997;15: Hershman DL et al J Clin Oncol 28: ; 28 Ovarian failure after chemotherapy Fig 1. Probability of menopause during the first year after diagnosis (from model shown in Table 3) Bone loss at 12 mos in Lumbar Spine 4 Normal menopausal Aromatase inhibitor Tamoxifen Chemo-induced OF GnH agonist % Goodwin, P. J. et al. J Clin Oncol; 17: Copyright American Society of Clinical Oncology 1) Warming et al Osteoporosis Int 13:15-12, 22; 2) Eastell et al J Bone Min es 21: , 26; 3) Shapiro et al J Clin Oncol 14:336-11, 21; 4) Fogelman et al Osteoporosis Int 14:11-6, 23 3
4 Bisphosphonates CALGB 7989 esults ** ** ** ** ** Osteoclast inhibitors Inhibit Activation Differentiation Binding to bone matrix Secretion H FDA-approved** Side Effects of zoledronic acid enal toxicity, fevers, pain Osteonecrosis % (5.3) -6.6 (6.9) % ZA control Trial Design: 7989 Stratifications Stage Tamoxifen ZA q3 mo Calcium/ Vit D Adj Chemo /- tamoxifen Calcium/ Vit D 12mo 24mo 36 mo andomized Bisphosphonate Trials Delmas Saarto Powles Fuleihan N Bisphosphonate isedronate vs. placebo Clodronate vs. control Clodronate vs. placebo Pamidronate vs. placebo Effect N=439 Calcium/ Vit D ZA q3 mo Calcium/ Vit D Hershman Shapiro Gnant Zoledronic acid vs. placebo Zoledronic acid vs. control Zoledronic acid vs. placebo 4
5 ABCSG Trial 12 Sources of Estrogen in Post Aromatase Inhibitor Zoledronic acid 4 mg Q6 mo x 3 years No Zoledronic acid Control Androgens Aromatase (CYP19) Estrogens Premenopausal, E GnH agonist TAM or Anastrozole Baseline T-score -2. postmenopausal Aromatase Adipose tissue, ovary; brain Brufsky et al J Clin Oncol 25:829-36; 27 ABCSG-12: BMD Fractures with Aromatase Inhibitors Trial N F/U (mo) Treatment Clinical Fracture ate (%) AI vs. TAM ATAC A vs. TAM 11. vs. 7.7 [p<.1] BIG LET vs. TAM 8.6 vs. 5.8 [p<.1] T scores: w/ ZA T AI after 2-3 years of TAM IES EXE vs. TAM 7. vs. 5. [p=.3] T scores: no ZA Tam AI ABCSG8/ ANO 3224 AI after 5 years of TAM 28 A vs. TAM 2. vs. 1. [p=.15] MA LET vs. Placebo 5.3 vs. 4.6 [p=.25] Gnant, M. F.X. et al. J Clin Oncol; 25:
6 Z-Fast /ZO-Fast Trial ZO-FAST Trial: 36 months Postmenopausal Age 6 years Letrozole 2.5 Baseline T-score -2. Zoledronic acid 4 mg Q6 mo Zoledronic acid only if T-score < -2 Upfront ZA (N=524) Delayed ZA (N=536) P-Value % Lumbar Spine <.1 BMD % Total Hip BMD <.1 All Fractures 26 (5%) 32 (6%).52 Brufsky et al J Clin Oncol 25:829-36; 27 Eidtmann, SABCS 28, Abstract 44 esults esults of Delayed Group Baseline BMD 36-month BMD (%) Normal Normal -1 to -2 < -2 Missing Osteopenic Only 15% of Delayed Group received Zoledronic Acid at 36 mo 6
7 SABE Trial: isk Stratification Anastrozole Does Chemotherapy Directly Contribute to Bone Loss? High isk T score -2. (n=38) Moderate isk (n=154) T score -1. to -2. isedronate isedronate Placebo Trial Saarto (1997) Shapiro (21) Fogelman (23) N Ovarian failure or Amenorrhea Mean or median % CI -8.9, -4.7 etained Menstrual Function Mean or median % CI -3., 1.2 Low isk (n=42) T score -1. Observation p=.1 Van Poznak et al, SABCS 27, Abstract 53 Abbreviations: Confidence Interval (CI) p=.1; p>.5; ** p= women anastrazole 1 mg T-score -1 to women Aromatase Inhibitor Mean T score ~1 Ibandronate 15 mg q month Placebo At 2 years LS spine: I vs. P ~6%, p<.2 Denosumab 6 mg sc q 6 month Placebo At 2 years LS spine: D vs. P ~ 8%, p<.1 Treatment of Bone Loss in Cancer Same recommendations as for non-cancer isk factor assessment Physical activity, calcium/vitamin D, stop smoking, reduce alcohol DEXA screening every 2 years Bisphosphonate treatment if indicated by T- score Consider stopping bisphosphonate with normalization of T-score Lester, JE et al; Clin Can es 28; Ellis et al J Clin Oncol 28 7
8 ASCO Approach to Bone Loss Exercise, stop smoking, supplemental calcium/vitamin D isk Factors Ovarian failure AI treatment Low risk High risk BMD of L/S spine and Hip by DEXA scan Healthy Lifestyle Monitor T-score 2. to 1 T score 2.5, or < 2. w/f Monitor BMD Start bisphosphonate DEXA Scans Treatments Bisphosphonates Hillner BE et al. J Clin Oncol. 23;21: When to start a bisphosphonate? ASCO 23: Start bisphosphonate -2.5 or lower New Guidelines being finalized; based NOFG Start bisphosphonate at 2 or lower Use T-score in hip/lumbar or femoral neck Individualize therapy -1.5 to -2 based on risk factors isk Factors: smoking; alcohol; sedentary; family history; chronic corticosteroids; being on AI Vitamin D and Vitamin D Deficiency Calcium and Vitamin D reduces fractures WHI randomized placebo-controlled trial and meta-analysis of trials of vitamin D /- calcium reduces fractures with 8 IU/day Vitamin D deficiency Common, caused by decreased sun exposure, intake, absorption ecent study in breast cancer survivors show low or deficient 25-OH in 76% (Healthy Eating, Eating, Activity and Lifestyle or HEAL study) Overall mean (/- SD) = 25 (1) ng/ml African-American = 18 (9) ng/ml Hispanics = 22 (9) ng/ml No consensus on measuring serum vitamin D Correcting D deficiency improves response to bisphosphonate Bishoff-Ferrari et al JAMA 293: , 25; Jackson et al N Eng J Med 354:669-83, 26; Neuhoser et al Am J Clin Nutrition 88:133-9, 28; Adami et al Osteoporosis Int June on-line; Geller et al Endocr Pract 14:293-7, 28 8
9 How well are we doing? 259 age < 5; 89 (34%) chemo-induced ovarian failure: ecommendations egular exercise 72% Calcium/vitamin D 57% DEXA scan 4% Conclusions Estrogen deprivation either through chemotherapyinduced ovarian failure, AI Health professionals should be: Familiar with recommendations to maintain bone health DEXA scans to screen for osteoporosis, and criteria for bisphosphonate treatment Generate appropriate referrals ecommendations for bone health (calcium, vitamin D, exercise, reduce smoking and alcohol) promote overall health Many unanswered questions: who needs a bisphosphonate?; what is the optimal timing, dose, and duration? Is ZA new standard for women on AI? Tham, XL et al Abs # 67, SABCS 25 What about Osteonecrosis? eported in 3-11% metastatic pts on IV bisphosphonates: Schedule (monthly), duration (> 2-3 years), drug (zoledronic acid), and dental procedure No effective treatments Prevention: dental exam; oral hygiene, avoid dental work Very rarely observed in adjuvant trials using 4 mg q3 or q6 months Prevention of Distant ecurrence by adjuvant Bisphosphonates Two Hypotheses: Indirect anti-tumor effects Bisphosphonates breaking the Vicious Cycle Direct anti-tumor effects 9
10 ABCSG Trial 12 Zoledronic acid 4 mg Q6 mo x 3 years No Zoledronic acid Control Bone micrometastasis is adverse prognostic factor Factors that regulate normal bone breakdown/ new bone formation are growth factors for tumor cells Premenopausal, E GnH agonist TAM or Anastrozole Baseline T-score -2. Yoneda BBC 25 Brufsky et al J Clin Oncol 25:829-36; 27 Stopping the Vicious Cycle H=.64 ( ) Adjuvant Bisphosphonate 1
11 Preclinical Data using Bisphosphonates In breast cancer cell lines: Inhibits adhesion, invasion Apoptosis Antiangiogenic activity: Synergistic anti-tumor effects: With CMF, taxanes, doxorubicin AZUE Demographics Premenopausal Endocrine Only Chemo Only Endo Chemo Anthracyclines N ZA Dosing ADJ TX (n=1678) ADJ TX ZA (n=1681) Q1 mo x 6; Q3 mo x 8; Q6 mo x 5 = 5 yr ABCSG-12 (n=181) 1 1 ~4 Q6 mo x 3 yr AZUE UK Trial Higher pc with ZA Stage II/III N=336 Closed 1/26 Adjuvant Therapy (Neo, Chemo, Endo) Adjuvant Therapy ZA Subset of 25 (<1%) received neoadjuvant N CT CT ZA P Tumor size mm pc (%) Mastectomy (%) Suggestive, but hardly definitive. Winter, SABCS 28, Abstract 511 Winter, SABCS 28, Abstract
12 Trial Diel 1998; 24 BM mets AZUE Completed Trials Powles 22; 26 Saarto 21, 24 NSAPB 34 N F/U (mo) Treatment Clod 16 mg vs. control x 2 yr Clod 16 mg vs. placebo x 2 yr Clod 16 mg vs. control x 3 yr Clod 166 mg vs. placebo x 3 yr ZA Q1 mo x 6; Q3 mo x 8; Q6 mo x 5 = 5 yr Outcome survival bone mets non-bone mets Is adjuvant ZA ready for prime time? Early Adapters Yes in everyone Yes, but only in premenopausal with endocrine therapy Late Adapters No one, until AZUE and NSAPB are reported Yes, but only in premenopausal with endocrine therapy Trial INTEGOUP BIG 4-4 GAIN Ongoing Trials N F/U (mo) Treatment ZA vs. Clod vs. Ibandronate capectibine /- Ibandronate CEP /- capectibine /- Ibandronate Outcome Conclusions Zoledronic acid has anti-tumor activity in preclinical studies and in the results of one a few clinical trials More information is expected soon with presentations of larger trials My opinion is that we need more data to understand whether zoledronic should be prescribed for its anti-tumor effects in clinic 12
Breast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationBreast Cancer and Bone Health. Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield
Breast Cancer and Bone Health Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield Breast Cancer and Bone Health Normal Bone Health Impact of Cancer Therapies on Bone Health Therapeutic
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationOsteoporosis management in cancer patients
Osteoporosis management in cancer patients Belgian Menopause Society - Osteoporosis - Brussels, Oct 2017 Prof. JJ Body CHU Brugmann Univ. Libre de Bruxelles Brussels Bone loss associated with hormone ablation
More informationAromatase Inhibitors & Osteoporosis
Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health
More information4.7 Studies of Quality Holy Cross Hospital Bone Health Early Stage I ER/PR Positive Breast Cancer Patients December 13, 2017
4.7 Studies of Quality Holy Cross Hospital 2017 Bone Health Early Stage I ER/PR Positive Breast Cancer Patients December 13, 2017 Bone Health in Stage I ER/PR Positive Breast Cancer Patients To review
More informationAdjuvant bisphosphonates: our recommendations
Adjuvant bisphosphonates: our recommendations Andreas Makris Mount Vernon Cancer Centre OPTIMA launch meeting, 27 April 2017 Breast Cancer Metastasis Tumour cell colonisation of bone Tumour cell proliferation
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationBisphosphonates and Breast Cancer
Bisphosphonates and Breast Cancer Bisphosphonates Analogues of pyrophosphate Carbon substitution makes them resistant to endogenous phosphatases in circulation Potent inhibitors of osteoclast growth, maturation
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationA Review of Bone Health Issues in Oncology
A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationMedication Associated Osteoporosis
Medication Associated Osteoporosis Drugs that are bad for the bones Jonathan Graf, MD Associate Professor of Clinical Medicine UCSF Director UCSF Rheumatoid Arthritis Clinic Necessary Therapies Preventable
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationBeyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO
Beyond the Break After Breast Cancer: Osteoporosis in Survivorship Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Disclosures No disclosures Osteoporosis in Breast Cancer Survivorship
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationIssues in Cancer Survivorship. Larissa A. Korde, MD, MPH June 26, 2010
Issues in Cancer Survivorship Larissa A. Korde, MD, MPH June 26, 2010 Estimated US Cancer Cases in Women: 2006-2008 CA Cancer J Clin 2006; 56:106-130; CA Cancer J Clin 2008;58:71 96. Relative Survival*
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationNew Developments in Oncology Bone Health. Learning Objectives. Disclosures 10/1/2014
New Developments in Oncology Bone Health Kamakshi V. Rao, Pharm.D., BCPOP, CPP, FASHP Clinical Manager, Pharmacy Residency Programs Oncology and Bone Marrow Transplant Clinical Pharmacist University of
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationBAD for the Bones Skeletal Woes from Commonly Prescribed Medications
BAD for the Bones Skeletal Woes from Commonly Prescribed Medications A Case of Skeletal Cruelty Phenobarbitol Arimidex Heparin Jonathan Graf, MD Asst. Professor Medicine, UCSF Div. Rheumatology, SFGH Prednisone
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationCurrent management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom
British Journal of Cancer (2006) 94, 30 35 All rights reserved 0007 0920/06 $0 www.bjcancer.com Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationLuminal early breast cancer: (neo-) adjuvant endocrine therapy
CAMPUS GROSSHADERN CAMPUS INNENSTADT KLINIK UND POLIKLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE DIREKTOR: PROF. DR. MED. SVEN MAHNER Luminal early breast cancer: (neo-) adjuvant endocrine therapy Nadia
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationManaging Skeletal Metastases
School of Breast Oncology 2012 Managing Skeletal Metastases Cathy Van Poznak, MD Assistant Professor University of Michigan Comprehensive Cancer Center Saturday, November 3, 2012 Learning Objectives: Define
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationSurviving Breast Cancer
Surviving Breast Cancer What to expect after completing treatment Dexter T. Estrada, MD Hematology Oncology Medical Group of Fresno, Inc. November 3, 2012 Epidemiology & Survival Estimates Breast cancer
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationHORMONAL THERAPY IN ADJUVANT CARE
ADVANCES IN ENDOCRINE THERAPY FOR BREAST CANCER* Matthew J. Ellis, MD, PhD ABSTRACT Endocrine therapy is used frequently in breast cancer management, particularly in the setting of adjuvant care, but outstanding
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationBone health a key factor in elderly and not so elderly patients with cancer
Bone health a key factor in elderly and not so elderly patients with cancer Matti S. Aapro IMO Genolier Switzerland COI Dr Aapro is a consultant for Amgen, BMS, Celgene, Eisai, Genomic Health, GSK, Helsinn,
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationUpdate from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002
Update from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002 Nearly 5,000 physicians, oncologists, radiologists, epidemiologists, basic scientists, and breast cancer advocates from
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationFollow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 19 April 2018 Disclosures
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationThe Use of Adjuvant Bisphosphonates in the Treatment of Early-Stage Breast Cancer
The Use of Adjuvant Bisphosphonates in the Treatment of Early-Stage Breast Cancer Aju Mathew, MD, MPhil, and Adam M. Brufsky, MD, PhD Aju Mathew, MD, MPhil, is the chief fellow in hematology and medical
More informationLa salute dell osso nelle pazienti in trattamento adiuvante. Airoldi Mario - S.C. Oncologia Medica 2 Città della Salute e della Scienza di Torino
La salute dell osso nelle pazienti in trattamento adiuvante Airoldi Mario - S.C. Oncologia Medica 2 Città della Salute e della Scienza di Torino BONE STRENGTH OSTEOPOROSIS SKELETAL DISORDER COMPROMISING
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationAETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents
AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationBone Protection and Improved Survival
Bone Protection and Improved Survival Professor Rob Coleman Weston Park Hospital Sheffield Cancer Research Centre University of Sheffield UK Trans Atlantique en Oncologie Paris November 20 th 21 st November
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationAdjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More informationEarly and locally advanced breast cancer: diagnosis and management
National Institute for Health and Care Excellence Draft for Consultation Early and locally advanced breast cancer: diagnosis and management [G] Evidence reviews for adjuvant bisphosphonates NICE guideline
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationMedical Review. The following slides were medically reviewed by Dr. Nancy Dawson in June 2018.
Bone Health Medical Review The following slides were medically reviewed by Dr. Nancy Dawson in June 2018. Presentation Overview 1. What is bone health? 2. How can cancer and cancer treatments affect your
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationBone Health in Adult Cancer Survivorship Maryam B. Lustberg, Raquel E. Reinbolt, and Charles L. Shapiro
VOLUME 30 NUMBER 30 OCTOBER 20 2012 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Bone Health in Adult Cancer Survivorship Maryam B. Lustberg, Raquel E. Reinbolt, and Charles L. Shapiro All authors:
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationRole of Pharmacists in Maintaining Bone Health in Patients with Cancer
Role of Pharmacists in Maintaining Bone Health in Patients with Cancer Presented as a Live Webinar Wednesday, April 17, 2013 1-2 pm EDT Planned and conducted by ASHP Advantage. Supported by an educational
More informationSummary REVIEW ARTICLE
Received: 30 March 2018 Revised: 1 May 2018 Accepted: 1 May 2018 DOI: 10.1111/cen.13735 REVIEW ARTICLE Assessment and management of bone health in women with oestrogen receptor- positive breast cancer
More informationBreast Cancer: Weight and Exercise. Anne McTiernan, MD, PhD. Fred Hutchinson Cancer Research Center Seattle, WA
Breast Cancer: Weight and Exercise Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA Associations of Obesity with Overall & Breast Cancer Specific Survival Survival Obese vs. Non-obese
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationOsteoporosis Update. Case 2. Case 1: Monday morning, 8:15
Osteoporosis Update Laura E. Ryan, MD Assistant Director for Special Programs Center for Women s Health Clinical Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationOSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC
OSTEOPOROSIS MANAGEMENT AND INVESTIGATION David A. Hanley, MD, FRCPC There is a huge care gap in the management of osteoporosis in this country. As yet unpublished findings from the Canadian Multicentre
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationBisphosphonates therapy (BT) in Early Breast Cancer & Establishing BT locally
Mr Matthew Rowland MA FRCS (Gen) National Oncoplastic Fellow RD&E Previous Breast, Endocrine & General Surgical trainee North West Deanery Bisphosphonates therapy (BT) in Early Breast Cancer & Establishing
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other PROLIA, XGEVA 37012 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request for prior authorization. All requests
More information